The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies
Open accessAbstract
OBJECTIVE: To systematically review published and unpublished efficacy studies of agomelatine in people with depression. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Literature search (Pubmed, Embase, Medline), Cochrane Central Register of Controlled Trials, European Medicines Agency (EMA) regulatory file for agomelatine, manufacturers of agomelatine (Servier). ELIGIBILITY CRITERIA: Double blind randomised placebo and comparator controlled trials of agomelatine in depression with standard depression rating scales. DATA SYNTHESIS: Studies were pooled by using a random effects model with DerSimonian and Laird weights for comparisons with placebo and comparator antidepressant. The primary efficacy measure (change in rating scale score) was summarised with standardised mean difference (SMD; a measure of effect size) and secondary outcome measures with relative risks. All results were presented with 95% confidence intervals. Statistical heterogeneity was explored by visual inspection of funnel plots and by the I(2) statistic. Moderators of effect were explored by meta-regression. RESULTS: We identified 20 trials with 7460 participants meeting inclusion criteria (11 in the published literature, four from the European Medicines Agency file, and five from the manufacturer). Almost all studies used the 17 item Hamilton depression rating scale (score 0-50). Agomelatine was significantly more effective than placebo with an effect size (SMD) of 0.24 (95% confidence interval 0.12 to 0.35) and relative risk of response 1.25 (1.11 to 1.4). Compared with other antidepressants, agomelatine showed equal efficacy (SMD 0.00, -0.09 to 0.10). Significant heterogeneity was uncovered in most analyses, though risk of bias was low. Published studies were more likely than unpublished studies to have results that suggested advantages for agomelatine. CONCLUSIONS: Agomelatine is an effective antidepressant with similar efficacy to standard antidepressants. Published trials generally had more favourable results than unpublished studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2021) · doi:10.1002/9781119558378 · Cited by 9,799
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
The National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Kirkham, J. J., Dwan, K. M., Altman, D. G., Gamble, C., Dodd, S., Smyth, R., & Williamson, P. R. (2010) · BMJ · doi:10.1136/bmj.c365 · Cited by 1,133
The Maudsley Prescribing Guidelines in Psychiatry
Taylor, D. M., Barnes, T. R. E., & Young, A. H. (2021) · Wiley eBooks · doi:10.1002/9781119870203 · Cited by 988
Self-citationAntidepressants and Body Weight: A Comprehensive Review and Meta-Analysis
Serretti, A., & Mandelli, L. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05346blu · Cited by 621
Eyding, D., Lelgemann, M., Grouven, U., Harter, M., Kromp, M., Kaiser, T., Kerekes, M. F., Gerken, M., & Wieseler, B. (2010) · BMJ · doi:10.1136/bmj.c4737 · Cited by 588
Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis
Serretti, A., & Chiesa, A. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a5233f · Cited by 583
Leucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451
L??o, H., Hale, A., & D??haenen, H. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00004 · Cited by 361
Meta-analysis of the placebo response in antidepressant trials.
Rief, W., Nestoriuc, Y., Weiss, S., Welzel, E., Barsky, A. J., & Hofmann, S. G. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.029 · Cited by 346
Goodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., & the Agomelatine Study Group (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04548 · Cited by 340
Sertraline versus other antidepressive agents for depression
Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006117.pub4 · Cited by 299
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
Kennedy, S. H., & Emsley, R. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.09.002 · Cited by 294
Mode of action of agomelatine: Synergy between melatonergic and 5-HT2Creceptors
Racagni, G., Riva, M. A., Molteni, R., Musazzi, L., Calabrese, F., Popoli, M., & Tardito, D. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.595823 · Cited by 282
Stahl, S. M., Fava, M., Trivedi, M. H., Caputo, A., Shah, A., & Post, A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05471blu · Cited by 262
Kasper, S., Hajak, G., Wulff, K., Hoogendijk, W. J. G., Montejo, A. L., Smeraldi, E., Rybakowski, J. K., Quera-Salva, M.-A., Wirz-Justice, A. M., Picarel-Blanchot, F., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05347blu · Cited by 257
Pierre Olié, J., & Kasper, S. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007766 · Cited by 256
Selective serotonin reuptake inhibitors and brain hemorrhage: A meta-analysis
Hackam, D. G., & Mrkobrada, M. (2012) · Neurology · doi:10.1212/wnl.0b013e318271f848 · Cited by 230
Lemoine, P., & Guilleminault, C. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1112 · Cited by 217
Kennedy, S. H., Rizvi, S., Fulton, K., & Rasmussen, J. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172b48c · Cited by 212
Montgomery, S. A., Kennedy, S. H., Burrows, G. D., Lejoyeux, M., & Hindmarch, I. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000137184.64610.c8 · Cited by 196
Restoring invisible and abandoned trials: a call for people to publish the findings
Doshi, P., Dickersin, K., Healy, D., Vedula, S. S., & Jefferson, T. (2013) · BMJ · doi:10.1136/bmj.f2865 · Cited by 190
Mirtazapine versus other antidepressive agents for depression
Watanabe, N., Omori, I. M., Nakagawa, A., Cipriani, A., Barbui, C., Churchill, R., & Furukawa, T. A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006528.pub2 · Cited by 158
Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy
THIERS, B. H. (2009) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)79042-7 · Cited by 157
Posternak, M. A., & Zimmerman, M. A. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.106.028555 · Cited by 155
Hale, A. S., Corral, R. M., Mencacci, C., Ruiz, J. S., Severo, C. A., & Gentil, V. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32833a86aa · Cited by 137
Zajecka, J., Schatzberg, A. F., Stahl, S. M., Shah, A., Caputo, A., & Post, A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d420a7 · Cited by 117
Heun, R., Ahokas, A., Boyer, P., Giménez-Montesinos, N., Pontes-Soares, F., Olivier, V., & Agomelatine Study Group (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08250 · Cited by 113
Koesters, M., Guaiana, G., Cipriani, A., Becker, T. M., & Barbui, C. (2013) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.112.120196 · Cited by 95
Stein, D. J., Ahokas, A., Albarran, C., Olivier, V., & Allgulander, C. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07493 · Cited by 94
Corruble, E., de Bodinat, C., Belaïdi, C., & Goodwin, G. M. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000679 · Cited by 94
Quera-Salva, M.-A., Hajak, G., Philip, P., Montplaisir, J., Keufer-Le Gall, S., Laredo, J., & Guilleminault, C. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328349b117 · Cited by 91
A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
Howland, R. H. (2011) · Drug Safety · doi:10.2165/11593960-000000000-00000 · Cited by 67
Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal
Singh, S. P., Singh, V., & Kar, N. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001301 · Cited by 60
Trowman, R., Dumville, J. C., Torgerson, D. J., & Cranny, G. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.014 · Cited by 59
The effects of agomelatine on sexual function in depressed patients and healthy volunteers
Montejo, A. L., Majadas, S., Rizvi, S. J., & Kennedy, S. H. (2011) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1243 · Cited by 53
Antidepressant efficacy of agomelatine versus SSRI/SNRI
Kasper, S. F., Corruble, E., Hale, A. S., Lemoine, P., Montgomery, S., & Quera-Salva, M.-A. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328359768e · Cited by 49
Demyttenaere, K., Corruble, E., Hale, A. S., Quera-Salva, M.-A., Picarel-Blanchot, F., & Kasper, S. F. (2013) · CNS Spectrums · doi:10.1017/s1092852913000060 · Cited by 44
Multiple Comparisons within a Study
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009) · Wiley eBooks · doi:10.1002/9780470743386.ch25 · Cited by 40
Antidepressants and Body Weight: A Comprehensive Review and Meta-Analysis
Ballenger, J. C. (2012) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/j.ypsy.2011.07.020 · Cited by 39
Antidepressant withdrawal symptoms—Telephone calls to a national medication helpline
Taylor, D., Stewart, S., & Connolly, A. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.04.026 · Cited by 37
Self-citationTreatment Emergent Sexual Dysfunction Related to Antidepressants: A Meta-analysis
Chiesa, A., Serretti, A., Calati, R., & Ronchi, D. D. (2009) · European Psychiatry · doi:10.1016/s0924-9338(09)70732-1 · Cited by 37
Gahr, M. L., Freudenmann, R. W., Connemann, B. J., Hiemke, C., & Schönfeldt‐Lecuona, C. (2013) · Pharmacopsychiatry · doi:10.1055/s-0033-1353156 · Cited by 34
The Association of Selective Serotonin Reuptake Inhibitors Use and Stroke in Geriatric Population
Hung, C., Lin, C., Lan, T., & Chan, C.-H. (2013) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.01.018 · Cited by 30
The efficacy of agomelatine in previously-treated depressed patients
Kasper, S. F., & Hajak, G. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.05.010 · Cited by 28
Ballenger, J. C. (2009) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)79307-1 · Cited by 23
Ballenger, J. C. (2011) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/j.ypsy.2010.10.061 · Cited by 20
Kasper, S. F., Hajak, G., Wulff, K., Hoogendijk, J. G., Montejo, A. L., Smeraldi, E., Rybakowski, J. K., Quera‐Salvá, M. A., Wirz‐Justice, A., Picarel-Blanchot, F., et al. (2011) · Cited by 18
Restoring invisible and abandoned trials: a call for people to publish the findings
(2013) · BMJ · doi:10.1136/bmj.f4223 · Cited by 14
A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12 weeks
Sparshatt, A., McAllister-Williams, H., Baldwin, D. S., et al. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12044 · Cited by 13
Self-citationMode of action of agomelatine: Synergy between melatonergic and 5-HT2C receptors
Racagni, G., Tardito, D., Riva, M. A., Molteni, R., Mallei, A., Musazzi, L., Calabrese, F., & Popoli, M. (2012) · BOA (University of Milano-Bicocca) · Cited by 11
Cited by
The chronic mild stress (CMS) model of depression: History, evaluation and usage
Willner, P. (2017) · Neurobiology of Stress · doi:10.1016/j.ynstr.2016.08.002 · Cited by 959
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Self-citationCircadian Mechanisms in Medicine
Allada, R., & Bass, J. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1802337 · Cited by 519
Leichsenring, F., Steinert, C., Rabung, S., & Ioannidis, J. P. A. (2022) · World Psychiatry · doi:10.1002/wps.20941 · Cited by 485
Spanagel, R. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.3/rspanagel · Cited by 221
Metadata
- Authors
- Taylor, D., Sparshatt, A., Varma, S., & Olofinjana, O.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2014-03-19
- Volume
- 348
- Issue
- mar19 5
- Pages
- g1888-g1888
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2068597369
- Cited by
- 334
- References
- 60
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.